ExpressPoints Biomarker-Driven Therapy for NSCLC: Experts Discuss Current and Future Trends

Download this short summary slideset of key takeaways from a live CCO Webinar featuring an overview of the current status of biomarkers guiding optimal use of targeted therapy and immunotherapy in the treatment of advanced NSCLC.
Jamie E. Chaft, MD
Stephen V. Liu, MD
Nathan Pennell, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.06 MB
Released: April 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
Lilly
Regeneron Pharmaceuticals, Inc & Sanofi Genzyme

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Download these expert-selected slides on slides on treating patients with NTRK-positive tumors with TRK inhibitors, from Clinical Care Options (CCO).

Alexander Drilon, MD Released: June 11, 2021

Download these expert-selected slides on slides on overcoming acquired resistance with TRK inhibitors, from Clinical Care Options (CCO).

Theodore Laetsch, MD Released: June 11, 2021

Download these expert-selected slides on testing for TRK fusions in your patients with cancer, from Clinical Care Options (CCO).

George D. Demetri, MD Released: June 11, 2021

Updated 2-year results from CheckMate 9LA evaluating nivolumab plus ipilimumab with chemotherapy vs chemotherapy from ASCO 2021, as reported by Clinical Care Options (CCO)

Released: June 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue